Zacks Research Comments on Omnicell FY2027 Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Research analysts at Zacks Research issued their FY2027 earnings estimates for Omnicell in a note issued to investors on Tuesday, February 25th. Zacks Research analyst R. Department expects that the company will post earnings per share of $1.36 for the year. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%.

A number of other research analysts also recently commented on the company. JPMorgan Chase & Co. increased their target price on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Wells Fargo & Company lowered their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Bank of America dropped their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. Benchmark restated a “buy” rating and set a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. Finally, Craig Hallum lifted their price target on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $52.33.

Omnicell Price Performance

Shares of Omnicell stock opened at $39.73 on Wednesday. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.74. The stock has a 50 day moving average of $42.65 and a 200 day moving average of $43.85. The firm has a market cap of $1.84 billion, a PE ratio of 147.15, a PEG ratio of 7.53 and a beta of 0.78.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Smartleaf Asset Management LLC raised its holdings in shares of Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after buying an additional 273 shares during the period. Johnson Financial Group Inc. bought a new position in Omnicell in the 4th quarter valued at $37,000. Van ECK Associates Corp increased its stake in Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after purchasing an additional 315 shares during the period. Headlands Technologies LLC bought a new stake in shares of Omnicell during the fourth quarter worth $53,000. Finally, First Horizon Advisors Inc. boosted its stake in shares of Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after purchasing an additional 355 shares during the period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Insider Activity

In related news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now directly owns 58,427 shares in the company, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 2.64% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.